Cargando…
A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura
Immune-mediated thrombotic thrombocytopenic purpura (iTTP), an autoantibody-mediated severe ADAMTS13 deficiency, is caused by insufficient proteolytic processing of von Willebrand factor (VWF) multimers (MMs) and microvascular thrombi. Recurrence of acute iTTP is associated with persistence or reapp...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471935/ https://www.ncbi.nlm.nih.gov/pubmed/37399489 http://dx.doi.org/10.1182/bloodadvances.2023010028 |
_version_ | 1785099962569195520 |
---|---|
author | Falter, Tanja Rossmann, Heidi de Waele, Laure Dekimpe, Charlotte von Auer, Charis Müller-Calleja, Nadine Häuser, Friederike Degreif, Adriana Marandiuc, Dana Messmer, Xavier Sprinzl, Martin Lackner, Karl J. Jurk, Kerstin Vanhoorelbeke, Karen Lämmle, Bernhard |
author_facet | Falter, Tanja Rossmann, Heidi de Waele, Laure Dekimpe, Charlotte von Auer, Charis Müller-Calleja, Nadine Häuser, Friederike Degreif, Adriana Marandiuc, Dana Messmer, Xavier Sprinzl, Martin Lackner, Karl J. Jurk, Kerstin Vanhoorelbeke, Karen Lämmle, Bernhard |
author_sort | Falter, Tanja |
collection | PubMed |
description | Immune-mediated thrombotic thrombocytopenic purpura (iTTP), an autoantibody-mediated severe ADAMTS13 deficiency, is caused by insufficient proteolytic processing of von Willebrand factor (VWF) multimers (MMs) and microvascular thrombi. Recurrence of acute iTTP is associated with persistence or reappearance of ADAMTS13 deficiency. Some patients remain in remission despite recurring or persisting severe ADAMTS13 deficiency. In a prospective 2-year observational study, we investigated VWF MM patterns and ADAMTS13 in patients with iTTP in remission and at acute episodes. Of the 83 patients with iTTP, 16 suffered 22 acute episodes whereas 67 remained in clinical remission during follow-up, including 13 with ADAMTS13 <10% and 54 with ADAMTS13 ≥10%. High -molecular weight to low-molecular weight VWF MM ratio based on sodium dodecyl sulfate-agarose gel electrophoresis was compared with ADAMTS13 activity. VWF MM ratio was significantly higher in patients in remission with <10% compared with ≥10% ADAMTS13 activity. Fourteen samples obtained from 13 to 50 days (interquartile range; median, 39) before acute iTTP onset (ADAMTS13 <10% in 9 patients and 10%-26% in 5) showed VWF MM ratios significantly higher than those from 13 patients remaining in remission with ADAMTS13 <10%. At acute iTTP onset, VWF MM ratio decreased significantly and was low in all patients despite <10% ADAMTS13. The VWF MM ratio does not depend exclusively on ADAMTS13 activity. The disappearance of high molecular weight VWF MMs resulting in low VWF MM ratio at iTTP onset may be explained by consumption of larger VWF MMs in the microcirculation. The very high VWF MM ratio preceding acute iTTP recurrence suggests that VWF processing is hampered more than in patients remaining in remission. |
format | Online Article Text |
id | pubmed-10471935 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The American Society of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-104719352023-09-02 A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura Falter, Tanja Rossmann, Heidi de Waele, Laure Dekimpe, Charlotte von Auer, Charis Müller-Calleja, Nadine Häuser, Friederike Degreif, Adriana Marandiuc, Dana Messmer, Xavier Sprinzl, Martin Lackner, Karl J. Jurk, Kerstin Vanhoorelbeke, Karen Lämmle, Bernhard Blood Adv Thrombosis and Hemostasis Immune-mediated thrombotic thrombocytopenic purpura (iTTP), an autoantibody-mediated severe ADAMTS13 deficiency, is caused by insufficient proteolytic processing of von Willebrand factor (VWF) multimers (MMs) and microvascular thrombi. Recurrence of acute iTTP is associated with persistence or reappearance of ADAMTS13 deficiency. Some patients remain in remission despite recurring or persisting severe ADAMTS13 deficiency. In a prospective 2-year observational study, we investigated VWF MM patterns and ADAMTS13 in patients with iTTP in remission and at acute episodes. Of the 83 patients with iTTP, 16 suffered 22 acute episodes whereas 67 remained in clinical remission during follow-up, including 13 with ADAMTS13 <10% and 54 with ADAMTS13 ≥10%. High -molecular weight to low-molecular weight VWF MM ratio based on sodium dodecyl sulfate-agarose gel electrophoresis was compared with ADAMTS13 activity. VWF MM ratio was significantly higher in patients in remission with <10% compared with ≥10% ADAMTS13 activity. Fourteen samples obtained from 13 to 50 days (interquartile range; median, 39) before acute iTTP onset (ADAMTS13 <10% in 9 patients and 10%-26% in 5) showed VWF MM ratios significantly higher than those from 13 patients remaining in remission with ADAMTS13 <10%. At acute iTTP onset, VWF MM ratio decreased significantly and was low in all patients despite <10% ADAMTS13. The VWF MM ratio does not depend exclusively on ADAMTS13 activity. The disappearance of high molecular weight VWF MMs resulting in low VWF MM ratio at iTTP onset may be explained by consumption of larger VWF MMs in the microcirculation. The very high VWF MM ratio preceding acute iTTP recurrence suggests that VWF processing is hampered more than in patients remaining in remission. The American Society of Hematology 2023-07-05 /pmc/articles/PMC10471935/ /pubmed/37399489 http://dx.doi.org/10.1182/bloodadvances.2023010028 Text en © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Thrombosis and Hemostasis Falter, Tanja Rossmann, Heidi de Waele, Laure Dekimpe, Charlotte von Auer, Charis Müller-Calleja, Nadine Häuser, Friederike Degreif, Adriana Marandiuc, Dana Messmer, Xavier Sprinzl, Martin Lackner, Karl J. Jurk, Kerstin Vanhoorelbeke, Karen Lämmle, Bernhard A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura |
title | A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura |
title_full | A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura |
title_fullStr | A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura |
title_full_unstemmed | A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura |
title_short | A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura |
title_sort | novel von willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura |
topic | Thrombosis and Hemostasis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471935/ https://www.ncbi.nlm.nih.gov/pubmed/37399489 http://dx.doi.org/10.1182/bloodadvances.2023010028 |
work_keys_str_mv | AT faltertanja anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT rossmannheidi anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT dewaelelaure anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT dekimpecharlotte anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT vonauercharis anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT mullercallejanadine anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT hauserfriederike anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT degreifadriana anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT marandiucdana anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT messmerxavier anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT sprinzlmartin anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT lacknerkarlj anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT jurkkerstin anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT vanhoorelbekekaren anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT lammlebernhard anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT faltertanja novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT rossmannheidi novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT dewaelelaure novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT dekimpecharlotte novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT vonauercharis novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT mullercallejanadine novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT hauserfriederike novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT degreifadriana novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT marandiucdana novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT messmerxavier novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT sprinzlmartin novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT lacknerkarlj novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT jurkkerstin novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT vanhoorelbekekaren novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura AT lammlebernhard novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura |